TY - JOUR
T1 - Intervention for unruptured high-grade intracranial dural arteriovenous fistulas
T2 - a multicenter study
AU - the Consortium for Dural Arteriovenous Fistula Outcomes Research
AU - Chen, Ching Jen
AU - Buell, Thomas J.
AU - Ding, Dale
AU - Guniganti, Ridhima
AU - Kansagra, Akash P.
AU - Lanzino, Giuseppe
AU - Giordan, Enrico
AU - Kim, Louis J.
AU - Levitt, Michael R.
AU - Abecassis, Isaac Josh
AU - Bulters, Diederik
AU - Durnford, Andrew
AU - Fox, W. Christopher
AU - Polifka, Adam J.
AU - Gross, Bradley A.
AU - Hayakawa, Minako
AU - Derdeyn, Colin P.
AU - Samaniego, Edgar A.
AU - Amin-Hanjani, Sepideh
AU - Alaraj, Ali
AU - Kwasnicki, Amanda
AU - van Dijk, J. Marc
AU - Potgieser, Adriaan R.E.
AU - Starke, Robert M.
AU - Sur, Samir
AU - Satomi, Junichiro
AU - Tada, Yoshiteru
AU - Abla, Adib A.
AU - Winkler, Ethan A.
AU - Du, Rose
AU - Lai, Pui Man Rosalind
AU - Zipfel, Gregory J.
AU - Sheehan, Jason P.
AU - Piccirillo, Jay F.
AU - Raman, Hari
AU - Lipsey, Kim
AU - Brinjikji, Waleed
AU - Vine, Roanna
AU - Cloft, Harry J.
AU - Kallmes, David F.
AU - Pollock, Bruce E.
AU - Link, Michael J.
AU - Patibandla, Mohana Rao
AU - Paisan, Gabriella
AU - Meyer, R. Michael
AU - Kelly, Cory
AU - Duffill, Jonathan
AU - Ditchfield, Adam
AU - Millar, John
AU - Macdonald, Jason
N1 - Funding Information:
Dr. Kansagra reports consultant fees from Medtronic and Penumbra and non–study-related clinical or research effort from MicroVention and Medtronic. Dr. Lanzino is a consultant for Superior Medical Editing and Nested Knowledge. Dr. Kim reports funding support from the NINDS, consultant fees from MicroVention, and stock ownership in SPI Surgical. Dr. Levitt reports funding support from the NINDS, AHA, Stryker, and Medtronic, and consultant fees from Medtronic, Minnetronix, and Metis Innovative; and ownership in Synchron, Cerebrotech, and Proprio. Dr. Polifka is a consultant for DePuy Synthes. Dr. Gross reports consultant fees from MicroVention and Medtronic. Dr. Derdeyn reports ownership in Pulse Therapeutics; is a consultant for Penumbra, Rapid Medical, and NoNo; and received clinical or research support for this study from Siemens Healthineers. Dr. Alaraj reports funding support from the NIH, and consultant fees from Cerenovus and Siemens. Dr. Starke reports funding support from NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, and the NIH, and consultant fees from Penumbra, Abbott, Medtronic, and Cerenovus.
Publisher Copyright:
© AANS 2022
PY - 2022/4
Y1 - 2022/4
N2 - OBJECTIVE The risk-to-benefit profile of treating an unruptured high-grade dural arteriovenous fistula (dAVF) is not clearly defined. The aim of this multicenter retrospective cohort study was to compare the outcomes of different interventions with observation for unruptured high-grade dAVFs. METHODS The authors retrospectively reviewed dAVF patients from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with unruptured high-grade (Borden type II or III) dAVFs were included and categorized into four groups (observation, embolization, surgery, and stereotactic radiosurgery [SRS]) based on the initial management. The primary outcome was defined as the modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were good outcome (mRS scores 0-2) at final follow-up, symptomatic improvement, all-cause mortality, and dAVF obliteration. The outcomes of each intervention group were compared against those of the observation group as a reference, with adjustment for differences in baseline characteristics. RESULTS The study included 415 dAVF patients, accounting for 29, 324, 43, and 19 in the observation, embolization, surgery, and SRS groups, respectively. The mean radiological and clinical follow-up durations were 21 and 25 months, respectively. Functional outcomes were similar for embolization, surgery, and SRS compared with observation. With observation as a reference, obliteration rates were higher after embolization (adjusted OR [aOR] 7.147, p = 0.010) and surgery (aOR 33.803, p < 0.001) and all-cause mortality was lower after embolization (imputed, aOR 0.171, p = 0.040). Hemorrhage rates per 1000 patient-years were 101 for observation versus 9, 22, and 0 for embolization (p = 0.022), surgery (p = 0.245), and SRS (p = 0.077), respectively. Nonhemorrhagic neurological deficit rates were similar between each intervention group versus observation. CONCLUSIONS Embolization and surgery for unruptured high-grade dAVFs afforded a greater likelihood of obliteration than did observation. Embolization also reduced the risk of death and dAVF-associated hemorrhage compared with conservative management over a modest follow-up period. These findings support embolization as the first-line treatment of choice for appropriately selected unruptured Borden type II and III dAVFs.
AB - OBJECTIVE The risk-to-benefit profile of treating an unruptured high-grade dural arteriovenous fistula (dAVF) is not clearly defined. The aim of this multicenter retrospective cohort study was to compare the outcomes of different interventions with observation for unruptured high-grade dAVFs. METHODS The authors retrospectively reviewed dAVF patients from 12 institutions participating in the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR). Patients with unruptured high-grade (Borden type II or III) dAVFs were included and categorized into four groups (observation, embolization, surgery, and stereotactic radiosurgery [SRS]) based on the initial management. The primary outcome was defined as the modified Rankin Scale (mRS) score at final follow-up. Secondary outcomes were good outcome (mRS scores 0-2) at final follow-up, symptomatic improvement, all-cause mortality, and dAVF obliteration. The outcomes of each intervention group were compared against those of the observation group as a reference, with adjustment for differences in baseline characteristics. RESULTS The study included 415 dAVF patients, accounting for 29, 324, 43, and 19 in the observation, embolization, surgery, and SRS groups, respectively. The mean radiological and clinical follow-up durations were 21 and 25 months, respectively. Functional outcomes were similar for embolization, surgery, and SRS compared with observation. With observation as a reference, obliteration rates were higher after embolization (adjusted OR [aOR] 7.147, p = 0.010) and surgery (aOR 33.803, p < 0.001) and all-cause mortality was lower after embolization (imputed, aOR 0.171, p = 0.040). Hemorrhage rates per 1000 patient-years were 101 for observation versus 9, 22, and 0 for embolization (p = 0.022), surgery (p = 0.245), and SRS (p = 0.077), respectively. Nonhemorrhagic neurological deficit rates were similar between each intervention group versus observation. CONCLUSIONS Embolization and surgery for unruptured high-grade dAVFs afforded a greater likelihood of obliteration than did observation. Embolization also reduced the risk of death and dAVF-associated hemorrhage compared with conservative management over a modest follow-up period. These findings support embolization as the first-line treatment of choice for appropriately selected unruptured Borden type II and III dAVFs.
KW - dural arteriovenous fistula
KW - embolization
KW - endovascular
KW - high grade
KW - intracranial
KW - radiosurgery
KW - surgery
KW - unruptured
KW - vascular disorders
UR - http://www.scopus.com/inward/record.url?scp=85128160857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128160857&partnerID=8YFLogxK
U2 - 10.3171/2021.1.JNS202799
DO - 10.3171/2021.1.JNS202799
M3 - Article
C2 - 34608140
AN - SCOPUS:85128160857
SN - 0022-3085
VL - 136
SP - 962
EP - 970
JO - Journal of neurosurgery
JF - Journal of neurosurgery
IS - 4
ER -